COMPANY:

Genecentric

"GeneCentric Therapeutics...announced upcoming presentations at the American Association for Cancer Research Annual Meeting 2024 being held in San Diego, California from April 5-10. Presentations will include a poster describing a new colorectal cancer predictive response signature (MSS-PRS) that selects tumors not identified with conventional MSI testing but have molecular characteristics consistent with microsatellite instability, making them a potential target for immune checkpoint inhibition. A second poster presentation describes ongoing clinical validation for PurISTSM, a novel RNA-expression test developed in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival with standard of care FOLFIRINOX than patients with the basal subtype of PDAC."

"GeneCentric Therapeutics...today announced upcoming presentations at the Precision Medicine World Conference (PMWC) in Santa Clara, California from January 24-26 and the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which will be held January 25-27 in San Francisco, California....'We look forward to sharing data about the ongoing discovery and development of our novel RNA-based signatures and tests at the PMWC and ASCO GU meetings,'..."

"GeneCentric Therapeutics...announced today the publication of initial results from the ongoing Piedmont study using real-world data in lung cancer to develop its novel RNA-based Antifolate Predictive Response Signature (AF-PRS), which is being co-developed as a clinical diagnostic test with Labcorp. The retrospective analysis was published in the peer-reviewed journal Clinical Cancer Research....The initial analysis focused on non-squamous non-small cell lung cancer (NS-NSCLC) patients treated with standard-of-care (SOC) pemetrexed/platinum doublet chemotherapy. Results showed over half (53%) of patients that were AF-PRS(+) had extended progression-free survival (PFS) versus those who were AF-PRS(-) (16.6 months vs. 6.6 months; P=0.025). Furthermore, the significant PFS difference was even more pronounced between AF-PRS(+) and AF-PRS(-) patients who were non-metastatic (36.2 months vs. 9.3 months; P=0.03)."

"GeneCentric Therapeutics...announced today that its PurIST^SM test is now commercially available through Tempus for clinical use. PurIST is a novel RNA-expression test that identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) who are likely to experience longer overall survival (OS) with standard-of-care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC."

"GeneCentric Therapeutics...announced today the initiation of its Alamance study, a multi-center bladder cancer study conducted in collaboration with investigators at Memorial Sloan Kettering Cancer Center and the University of Wisconsin – Madison Carbone Cancer Center....In this prospectively designed real-world evidence study, clinical response data and existing tumor samples are being collected from a multi-center cohort of approximately 250 patients with locally advanced or metastatic urothelial (bladder) cancer treated with FGFR-targeted therapy (e.g., erdafitinib) or other standards of care (e.g., anti-PD-(L)1 or platinum-based chemotherapy)."

"GeneCentric Therapeutic...announced today the poster presentation of further clinical validation data for PurIST^SM, a novel RNA-expression test, in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival (OS) with standard of care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC. The presentation will be made at the 8th AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, which runs from September 13-16, 2022."